CCL2 is initially described as a “tumor-derived chemotactic factor”, and has been shown to be a potent chemoattractant for several types of immune cells, including the monocytes, natural killer cells, memory T cells, and immature dendritic cells, thereby mediating multiple proinflammatory effects and neoangiogenesis [44–50]. Here, CCL2 is linked to neoplasm.